Data / Drug companies / Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd.: 61 products in the FDA NDC directory, labeler code 67184
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Qilu Pharmaceutical Co., Ltd. (labeler code 67184) lists 61 products in the FDA National Drug Code Directory, covering 29 finished drugs by generic name. By type: 58 prescription drugs, 3 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 3, 2026.
The request: Watch Qilu Pharmaceutical Co., Ltd. (FDA labeler code 67184): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 67184
- Products in commercial distribution
- 61
- Packages
- 73
- Finished drugs by generic name
- 29
- Prescription products
- 58
- Over the counter products
- 0
- Flagged as original packager
- 53 of 53 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- September 8, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 58 | 95.1% |
| Bulk ingredients | 3 | 4.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 58 | 95.1% |
| Bulk ingredients | 3 | 4.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Olanzapine | 7 | 49 |
| Oxaliplatin | 5 | 16 |
| Ceftriaxone sodium | 4 | 12 |
| Tadalafil | 4 | 54 |
| Irinotecan hydrochloride | 3 | 12 |
| Cefepime hydrochloride | 3 | 4 |
| Micafungin | 2 | 6 |
| Bumetanide | 2 | 42 |
| Palonosetron hydrochloride | 2 | 11 |
| Imatinib mesylate | 2 | 17 |
| Doxorubicin hydrochloride | 2 | 20 |
| Pemetrexed disodium | 2 | 14 |
| Mirabegron | 2 | 10 |
| Amikacin sulfate | 2 | 6 |
| Cyclosporine | 2 | 24 |
| Hydroxyurea | 1 | 14 |
| Ondansetron | 1 | 52 |
| Gefitinib | 1 | 5 |
| Daptomycin | 1 | 25 |
| Solifenacin succinate tablets | 1 | 1 |
| Bortezomib | 1 | 26 |
| Ganirelix acetate | 1 | 10 |
| Cetrorelix acetate for injection | 1 | 2 |
| Nicardipine hydrochloride | 1 | 27 |
| Decitabine | 1 | 18 |
| Icosapent ethyl | 1 | 21 |
| Melphalan hydrochloride | 1 | 14 |
| Fosaprepitant dimeglumine | 1 | 12 |
| Cefazolin | 1 | 11 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 11 | 18% |
| Injection, powder, lyophilized, for solution | 10 | 16.4% |
| Injection, powder, for solution | 9 | 14.8% |
| Tablet | 8 | 13.1% |
| Tablet, film coated | 5 | 8.2% |
| Injection | 4 | 6.6% |
| Powder | 3 | 4.9% |
| Capsule | 2 | 3.3% |
| Injection, suspension, liposomal | 2 | 3.3% |
| Kit | 2 | 3.3% |
| Tablet, film coated, extended release | 2 | 3.3% |
| Capsule, liquid filled | 2 | 3.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Doxorubicin hydrochloride | 67184-0624 | Injection, suspension, liposomal | Generic drugs (ANDA) | February 3, 2026 |
| Doxorubicin hydrochloride | 67184-0623 | Injection, suspension, liposomal | Generic drugs (ANDA) | February 3, 2026 |
| Olanzapine | 67184-0573 | Injection, powder, for solution | Generic drugs (ANDA) | November 11, 2025 |
| Nicardipine Hydrochloride | 67184-0611 | Injection, solution | Generic drugs (ANDA) | October 28, 2025 |
| Cyclosporine | 67184-0585 | Capsule, liquid filled | Generic drugs (ANDA) | September 15, 2025 |
| Cyclosporine | 67184-0584 | Capsule, liquid filled | Generic drugs (ANDA) | September 15, 2025 |
| Mirabgeorn | 67184-0572 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 30, 2025 |
| Mirabegron | 67184-0571 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 30, 2025 |
| Ganirelix Acetate | 67184-0574 | Injection, solution | Generic drugs (ANDA) | May 15, 2025 |
| Micafungin | 67184-0590 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 3, 2025 |
| Micafungin | 67184-0589 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 3, 2025 |
| Icosapent Ethyl | 67184-0582 | Capsule | Generic drugs (ANDA) | January 1, 2025 |
| Bumetanide | 67184-0594 | Injection | Generic drugs (ANDA) | September 19, 2024 |
| Bumetanide | 67184-0593 | Injection | Generic drugs (ANDA) | September 19, 2024 |
| Cetrorelix acetate | 67184-0605 | Kit | Generic drugs (ANDA) | April 16, 2024 |
| Amikacin Sulfate | 67184-0570 | Injection, solution | Generic drugs (ANDA) | March 19, 2024 |
| Amikacin Sulfate | 67184-0569 | Injection, solution | Generic drugs (ANDA) | March 19, 2024 |
| Hydroxyurea | 67184-0607 | Capsule | Generic drugs (ANDA) | March 6, 2024 |
| Melphalan Hydrochloride | 67184-0618 | Kit | Generic drugs (ANDA) | December 18, 2023 |
| Gefitinib | 67184-0531 | Tablet, coated | Generic drugs (ANDA) | February 13, 2023 |
| Imatinib mesylate | 67184-0533 | Tablet | Generic drugs (ANDA) | June 21, 2022 |
| Imatinib mesylate | 67184-0532 | Tablet | Generic drugs (ANDA) | June 21, 2022 |
| Pemetrexed | 67184-0504 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 25, 2022 |
| Pemetrexed | 67184-0503 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 25, 2022 |
| Bortezomib | 67184-0530 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.